Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix has reported its latest shareholder information in compliance with French regulations. As of
Nanobiotix reported significant operational advancements and financial results for H1 2021. The Company achieved an impressive 82.5% overall objective response rate and 62.5% complete response rate in vulnerable elderly patients from Study 102, supporting a pivotal Phase III study set to commence in late Q4 2021.
Financially, cash and equivalents totaled €102.3 million, expected to fund operations into Q1 2023. However, net loss increased to €30.4 million, reflecting higher R&D and SG&A expenses. Revenue stood at €9.7 thousand, a decrease from the previous year.
NANOBIOTIX (NASDAQ: NBTX), a biotechnology firm focused on cancer treatment, announced that CEO Laurent Levy will present the company's latest developments at the virtual H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be accessible on-demand starting at 7:00 AM EDT on September 13, 2021. The company is known for its innovative physics-based therapeutic approaches and holds numerous patents in oncology and other fields. For further details, visit www.nanobiotix.com.
NANOBIOTIX (NASDAQ: NBTX) reported its operational progress and cash position for Q2 2021, revealing total revenue of €9.7k for the first half, a significant drop from €36.9k in H1 2020. The company’s cash reserves decreased slightly to €102.3 million, bolstered by a €20 million upfront payment from its collaboration with LianBio. Key operational highlights included promising clinical data for NBTXR3 in head and neck cancer, as well as a strategic partnership with LianBio for development in Asia. A pivotal phase III study for NBTXR3 is planned in late 2021.
NANOBIOTIX (NASDAQ: NBTX) announced the initiation of a phase I clinical study of NBTXR3 combined with radiation therapy for treating inoperable recurrent non-small cell lung cancer (NSCLC). This study is one of five recruiting collaborations at The University of Texas MD Anderson Cancer Center. NBTXR3, a unique oncology product, is designed to enhance tumor cell death through a one-time intratumoral injection. The company aims to expand NBTXR3's applications across solid tumors while focusing on head and neck cancer and immunotherapy.
NANOBIOTIX (NASDAQ: NBTX) announced a virtual KOL event on June 11, 2021, at 8 AM ET, targeting analysts, investors, and the scientific community. The event will showcase key opinion leaders discussing the immunotherapy data from the 2021 ASCO Annual Meeting and the first-in-class radioenhancer NBTXR3's role in oncology. Highlights include presentations on NBTXR3's mode of action, safety and efficacy updates, and its potential as a combination-agnostic product. Registration for the event is open, and the webcast will be available for later viewing.
Nanobiotix (NASDAQ: NBTX) announced updated data on its immunotherapy product NBTXR3 at the 2021 ASCO Meeting. The data shows promising results in treating advanced cancer patients with NBTXR3 combined with radiotherapy and anti-PD-1 therapy. Out of 13 evaluable patients, 76.9% demonstrated tumor regression. Notably, 80% of anti-PD-1 naïve patients had tumor regression, and 75% of previously resistant patients showed tumor regression. The study supports NBTXR3's potential to enhance immune responses against cancer, addressing significant unmet needs in immunotherapy.
Nanobiotix (NASDAQ: NBTX) has appointed Bart Van Rhijn as the new CFO, succeeding Philippe Mauberna, who served for eight years. Van Rhijn comes with a strong background in financial management and business development, particularly in the pharmaceutical sector. His leadership is expected to facilitate the launch of the company’s second clinical registration study for NBTXR3 in head and neck cancer and to support expansion in immunotherapy and other solid tumor therapies. Mauberna will remain temporarily to assist during this transition.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company, announced that CEO Laurent Levy will present the company's latest developments at the Jefferies Virtual Healthcare Conference on June 4 at 8:00 AM ET (14:00 CET). The event will be available via a live webcast and an archived recording on the company’s website. Nanobiotix focuses on innovative physics-based treatments for cancer and is known for its lead candidate NBTXR3, which has received market authorization in Europe for treating soft tissue sarcoma under the brand name Hensify®.
Nanobiotix (NASDAQ: NBTX) announced the appointment of Dr. Gary Phillips as the new chairman of its supervisory board, succeeding Laurent Condomine. Dr. Phillips brings extensive experience from his roles at OrphoMed and Mallinckrodt Pharmaceuticals. His appointment coincides with the company's strategic focus on advancing its development programs, particularly in head and neck cancer and immunotherapy. Condomine, who led the board for 11 years, oversaw significant milestones, including the launch of NBTXR3, which has received European market authorization. This leadership transition is expected to enhance Nanobiotix's growth trajectory.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
